SANOFI ADR

NASDAQ: SNY (Sanofi)

Last update: 05 Jul, 12:00AM

48.30

-1.01 (-2.05%)

Previous Close 49.31
Open 48.70
Volume 1,555,600
Avg. Volume (3M) 2,654,747
Market Cap 118,483,279,872
Price / Earnings (TTM) 16.37
Price / Earnings (Forward) 10.98
Price / Sales 2.31
Price / Book 1.48
52 Weeks Range
45.80 (-5%) — 60.12 (24%)
Earnings Date 31 Jul 2025
TTM Dividend Yield 4.58%
Profit Margin 13.95%
Operating Margin (TTM) 20.78%
Diluted EPS (TTM) 2.94
Quarterly Revenue Growth (YOY) -4.60%
Quarterly Earnings Growth (YOY) 65.20%
Total Debt/Equity (MRQ) 23.01%
Current Ratio (MRQ) 1.46
Operating Cash Flow (TTM) 9.08 B
Levered Free Cash Flow (TTM) -4.94 B
Return on Assets (TTM) 4.28%
Return on Equity (TTM) 7.30%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Mixed
Drug Manufacturers - General (Global) Mixed Mixed
Stock Sanofi Mixed Bullish

AIStockmoo Score

1.2
Analyst Consensus NA
Insider Activity NA
Price Volatility 1.5
Technical Moving Averages 0.0
Technical Oscillators 2.0
Average 1.17

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
SNY 118 B 4.58% 16.37 1.48
AZN 226 B 2.13% 29.27 5.54
AMGN 159 B 3.13% 24.16 20.85
GILD 141 B 2.76% 23.78 7.18
GRFS 6 B 1.73% 28.00 1.13
BIIB 19 B - 12.73 1.13

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Core
% Held by Institutions 10.49%

No data within this time range.

No data within this time range.

Date Type Details
29 Aug 2025 Announcement Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
29 Aug 2025 Announcement Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
26 Aug 2025 Announcement New Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week
18 Aug 2025 Announcement Sanofi: Information concerning the total number of voting rights and shares - July 2025
14 Aug 2025 Announcement Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
14 Aug 2025 Announcement Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
06 Aug 2025 Announcement Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
06 Aug 2025 Announcement Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
31 Jul 2025 Announcement Press release: Online availability of Sanofi’s half-year financial report for 2025
31 Jul 2025 CNBC Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
31 Jul 2025 Announcement Press release: Online availability of Sanofi’s half-year financial report for 2025
31 Jul 2025 Announcement Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
31 Jul 2025 Announcement Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
30 Jul 2025 Announcement Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
30 Jul 2025 Announcement Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
25 Jul 2025 Announcement Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
25 Jul 2025 Announcement Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
23 Jul 2025 CNBC U.S. to remove mercury preservative from flu shots following RFK Jr. vaccine panel vote 
22 Jul 2025 Announcement Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
22 Jul 2025 Announcement Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
22 Jul 2025 Announcement BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study
18 Jul 2025 Announcement Press Release: Sanofi completes acquisition of Blueprint Medicines
18 Jul 2025 Announcement Press Release: Sanofi completes acquisition of Blueprint Medicines
17 Jul 2025 Announcement Press Release: Sanofi announces extension of Blueprint tender offer
17 Jul 2025 Announcement Press Release: Sanofi announces extension of Blueprint tender offer
16 Jul 2025 Announcement Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
16 Jul 2025 Announcement Press Release: Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
09 Jul 2025 Announcement Sanofi: Information concerning the total number of voting rights and shares - June 2025
01 Jul 2025 Announcement Adagene announces up to $25 million strategic investment from Sanofi
30 Jun 2025 Announcement Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
30 Jun 2025 Announcement Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
30 Jun 2025 Announcement Press release: Availability of the Q2 2025 Aide mémoire
30 Jun 2025 Announcement Press release: Availability of the Q2 2025 Aide mémoire
26 Jun 2025 CNBC RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants
26 Jun 2025 Announcement Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts
25 Jun 2025 Announcement Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
25 Jun 2025 Announcement Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
23 Jun 2025 Announcement Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
23 Jun 2025 Announcement Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
20 Jun 2025 Announcement Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
20 Jun 2025 Announcement Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
18 Jun 2025 CNBC RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
17 Jun 2025 Announcement Press release: Sanofi successfully prices €1.5 billion bond issue
17 Jun 2025 Announcement Press release: Sanofi successfully prices €1.5 billion bond issue
15 Jun 2025 Announcement Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
15 Jun 2025 Announcement Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
09 Jun 2025 Announcement Sanofi: Information concerning the total number of voting rights and shares - May 2025
09 Jun 2025 Announcement Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
09 Jun 2025 Announcement Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
09 Jun 2025 CNBC FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
05 Jun 2025 Announcement Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
03 Jun 2025 Announcement Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
03 Jun 2025 Announcement Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
03 Jun 2025 Announcement Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
03 Jun 2025 Announcement Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
02 Jun 2025 Announcement Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
02 Jun 2025 Announcement Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
02 Jun 2025 Announcement Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Show more
TTM Dividend Yield 4.58%
5Y Average Dividend Yield 4.78%
Payout Ratio 75.37%
Expected Next Dividend Payment Jun 2026
Ex Date Announcement Date Payment Date Details
09 May 2025 15 Apr 2025 12 Jun 2025 2.212154 Cash
09 May 2024 26 Mar 2024 06 Jun 2024 2.037356 Cash
09 May 2024 26 Mar 2024 06 Jun 2024 2.0369079 Cash
30 May 2023 - 23 Jun 2023 1.9000852 Cash
26 May 2022 - 27 Jun 2022 0.2971788 Cash
04 May 2022 20 Apr 2022 31 May 2022 1.7967514 Cash
03 May 2021 23 Mar 2021 26 May 2021 1.906064 Cash
30 Apr 2020 05 Mar 2020 26 May 2020 1.6993994 Cash
07 May 2019 - 31 May 2019 1.722322 Cash
09 May 2018 07 Feb 2018 04 Jun 2018 1.860874 Cash
11 May 2017 16 Feb 2017 07 Jun 2017 1.577088 Cash
05 May 2016 19 Feb 2016 01 Jun 2016 1.630252 Cash
06 May 2015 25 Feb 2015 02 Jun 2015 1.618087 Cash
17 May 2010 12 Feb 2010 14 Jun 2010 1.62732 Cash
04 Jun 2007 05 Mar 2007 03 Jul 2007 1.14537 Cash
02 Jun 2006 06 Mar 2006 03 Jul 2006 0.912 Cash
02 Jun 2005 01 Mar 2005 01 Jul 2005 0.7993 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 2.21 1 4.58
2024 4.07 2 8.45
2023 1.90 1 3.82
2022 2.09 2 4.32
2021 1.91 1 3.81
2020 1.70 1 3.50
2019 1.72 1 3.43
2018 1.86 1 4.29
2017 1.58 1 3.67
2016 1.63 1 4.03
2015 1.62 1 3.79
2010 1.63 1 5.05
2007 1.15 1 2.52
2006 0.912 1 1.98
2005 0.799 1 1.82
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria